Previous 10 | Next 10 |
2024-02-12 11:41:12 ET More on Incyte Incyte: Overly Reliant On Jakafi Despite Positive Phase 2 Results For Axatilimab Incyte buys global rights for tafasitamab from MorphoSys Agilent, Incyte to collaborate on companion diagnostics development Seeking Alpha...
2024-02-07 08:55:30 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – February 7, 2024 – USA News Group – One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer ...
2024-02-05 17:52:08 ET More on Incyte Incyte: Overly Reliant On Jakafi Despite Positive Phase 2 Results For Axatilimab Agilent, Incyte to collaborate on companion diagnostics development Why did Incyte stock go up today? Positive drug study Seeking Alpha ...
2024-02-05 17:02:22 ET Novartis ( NYSE: NVS ) said it will acquire cancer drugmake r MorphoSys AG ( MOR ) for EUR 68/share, or an aggregate of EUR 2.7B.... Read the full article on Seeking Alpha For further details see: Novartis to buy cancer drugmaker Mo...
– Tafasitamab is approved in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and is currently in Phase 3 trials for multiple indications Incyte (Nasdaq:INCY) announced it has entered into an asset purchase agreeme...
2024-02-05 10:24:24 ET More on MorphoSys MorphoSys: Positive Pelabresib Data Finally Unlocking Upside MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis MorphoSys: Buying Constellation Was A Desperate Measure MorphoSys expects 20...
2024-01-30 08:45:08 ET Agilent Technologies ( NYSE: A ) and Incyte ( NASDAQ: INCY ) have collaborated to develop advanced companion diagnostics in hematology and oncology.... Read the full article on Seeking Alpha For further details see: Agilent, Incyte ...
2024-01-24 14:39:16 ET More on S&P 500 Index: Bullard Says A March Rate Cut Looks Prudent PBOC Cuts Reserve Requirements, But USD Pullback May Offer New Buying Opportunity In North America SPY: Black Swan Hiding In Plain Sight Walmart is the least shorted...
2024-01-23 17:10:35 ET Summary Merus N.V. shares have remained strong despite negative safety news about its MCLA-129 program, as attention shifts to promising candidates petosemtamab and zenocutuzumab. Petosemtamab shows solid overall response rates for head and neck cancer, whil...
Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2023 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 13, 2024. The schedule for the press release and conference call/webcast is as follows: Q4 & YE 2023 Pr...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...